OncoResponse to Present at BioCentury Future Leaders Conference

HOUSTON, Texas – April 4, 2017 – OncoResponse, an immuno-oncology antibody discovery company, today announced that Chief Executive Officer Clifford J. Stocks will present an update on the Company and the status of its discovery and development pipeline at the 24th annual Future Leaders in the Biotech Industry conference hosted by BioCentury. The presentation will take place at 11:00am ET on April 7, 2017 at the Millennium Broadway hotel in New York City, NY.

OncoResponse utilizes a clinically validated platform technology to rapidly screen antibodies made by the human immune system and identify those antibodies with exceptional activity to cancer from elite responders following immunotherapy. The Company has a strategic alliance with the MD Anderson Cancer Center, which provides broad access to patient samples across multiple cancer indications and to oncology and translational medicine expertise including clinical and regulatory advice.

OncoResponse recently closed a $22.5 million Series A financing with a syndicate of blue chip venture capital and strategic investors including MD Anderson Cancer Center, ARCH Venture Partners, GreatPoint Ventures, Helsinn Investment Fund, Shire, Canaan Partners, HT Family Office (of China), Alexandria Real Estate Equities and William Marsh Rice University.

About OncoResponse

OncoResponse mines the human adaptive immune system to discover therapeutic antibodies against novel immuno-oncology targets. By identifying candidates from the immune systems of patients who have responded exceptionally well to cancer immunotherapies, OncoResponse has the potential to discover and develop drugs that can increase the success rate of these therapies across multiple cancer types. www.oncoresponseinc.com.

Media Contacts:
For OncoResponse, Inc.:
Casey Doucette
MacDougall Biomedical Communications
781-235-3060
cdoucette@macbiocom.com